NCT06741553 · RECRUITING
Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab
This study follows people with early Alzheimer's who are already choosing to take lecanemab, an antibody drug that targets amyloid in the brain. Researchers will track brain scans, memory and thinking changes, and side effects like brain swelling or bleeding. It is an observational study, so it watches what happens rather than testing the drug against a placebo.
You may qualify if
- Mini-Mental State Examination (MMSE) score between 22 and 30, Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score between 0.5 and 1;
- Confirmation of positive amyloid pathology by Amyloid-PET or cerebrospinal fluid Aβ testing;
- Completion of APOE gene testing.
- Willingness to use Lecanemab.
You're excluded if
- Unable to tolerate MRI scans;
- MRI showing hemorrhagic manifestations, including >4 microbleeds, surface iron deposition in any region, previous major hemorrhage, or potential brain lesions or vascular malformations;
- Use of anticoagulants or antiplatelet drugs, presence of hemorrhagic diseases, or any other conditions that increase the risk of central nervous system bleeding;
- With unstable physical conditions, unstable mental disorders, or those who are pregnant or breastfeeding.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-03